This opportunity is no longer accepting applications.
grant PAR-22-030

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

The URGenT network offers funding for studies and planning activities that support the development of new gene-based or transcript-directed therapies for ultra-rare neurological or neuromuscular disorders. The aim is to advance promising therapies that have strong biological support and proven effectiveness in relevant model systems, helping them progress towards regulatory approval and the st…

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare…

Funding Source

Agency: National Institutes of Health
Program: SBIR

Dates

Opportunity Released: November 9, 2021
Open for Submission: November 9, 2021
Submission Deadline: October 11, 2024
Application Window Closes: October 11, 2024

Documents

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.